Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma
Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma
Active, not recruiting · NCT05864742 · Registry updated 2024-08-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma | Mantle Cell Lymphoma Refractory | Active, not recruiting | Phase 2 | 2024-08-12 | NCT05864742 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Peter MacCallum Cancer Centre, Australia | 48 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Flinders Medical Centre | Bedford Park | Australia | 72 |
| Peter MacCallum Cancer Centre | Parkville | Australia | 2 |
| Princess Alexandra Hospital | Woolloongabba | Australia | 106 |